DAWA’S ONGOING PROJECTS

REFURBISHMENT: DAWA has invested in a $15 million refurbishment of a production facility to bring it in line with European standards. The facility, that is 20 years old, aims to adopt more automation and allow a 50 percent increase in production so that DAWA can accommodate more people in need.

GROWTH IN ETHIOPIA:

With a huge population of

100 million, Ethiopia remains less advanced with regards to pharmaceuticals. There are only around eight manufacturers and they produce at a local level, and DAWA is developing and investing itself in the nation to better reach its people. Collaborating with an investor, the business is setting up a manufacturing facility with access to an industrial park, aiming to have it completed and live by the start of 2024.

MERCK PROJECT IN KENYA: With help from the German government, DAWA is setting up a biotech facility in Kenya (connected to another Germanaided facility in Ghana). This facility will work with producing vaccines for a variety of diseases and viruses. The German-DAWA investment into the country is estimated to end up as €30 million in total by the project’s end.